We investigated the diagnostic significance of UDP-Z>-xylose: proteoglycan core protein ß-£>-xylosyltransferase (EC 2.4.2.26) in different chronic joint diseases. This eiizyme is located almost exclusively within chondrocytes, where it initiales the formation of chondroitin sulphate during the biosynthesis of proteoglycans and from which it is easily released after damage of articular cartilage.
Introduction
rate^limiting
Step, which involves the transfer of xy-™ . ... i u * -* · *· i *· l°s e fr°m UDP-xylose to serine hydroxyl groups in Chondroitin sulphate is present in the articular carti-, . / , , , , . ,-r \ " * r i*· t · * "i" · the core protein, is catalysed by this enzyme (3 -5) . läge äs a component of a inulticham prQtepglycan in ' r which the carbohydräte moiety is covalently bound We examined the diagnostic significance of xylosylto a core protein. In the biosynthesis of chondroitio transferase äs a clinical-chemical parameter in sulphate proteoglycan severäl glycosyltransferases chronic joint diseases, since the enzyme is highly and sulphotransferases are involved, ineluding ÜDP-specific to cells, which are able to synthesize proteo--D-xylose: proteoglycan core protein ß-Z)-xylosyl-glycans, especially to chondrocytes in articular cartitransferase (EC 2A2.26) (l, 2). The initial, apparently läge. In these cells the Xylosyltransferase seems to be s'
only weakly bound to the membranes of the rough endoplasmic reticulum (6) , from which it is released easily after disruption of the cells. Since destruction of articular cartilage is the common pathogenic process of all chronic joint diseases, the activity of xylosyltransferase in synovial fluids of patients with chronic joint diseases will indicate the extent of cartilage destruction.
Some of the results presented in this paper have been published previously äs a sjhort communication (7) . 
Materials and Methods

Sample preparation
Synovial fluid
Samples of synovial fluid were centrifuged immediately after aspiration of the synovial fluid from the knee joint at 1000g for 10 min at 4 °C to remove the synovial cells. The supernate was centrifuged again at 5000 g for 10 min at 4 °C to remove any remaining cells and ceil fragments. Total absence of cells was checked by light microscopy and tne supernate was stored at -70 °C until assayed. In order to diminish the viscosity of the synovial fluids, l ml of synoviai fluid was depolymerized by preincubation with 10 (33 units) of hyaluronate-4-glycanohydrolase for 20 min at 37 °C before furtner investigation. From control experiments a possible interference of hyaluronate-4^glycanohydrolase with Xylosyltransferase activity could be excluded.
Serum
Venous blood samples were collected in plastic tubes containing polystyrol beads (serum monovettes, Sarstedt, Nümbrecht, FRG). Serum was separated from blood cells by centrifugatiön (5000g; 4°C; 10 min) within l h. The samples were stored in several aliquots at -70 °C until analysed.
Plasma
Venous blood was drawn into EDTA^coated tubes and centrifuged at 5000g for 10 min at 4°C within l h after blood sampling. The plasma was frozen in plastic tubes at -70 °C.
Tissue extractfrom human costal cartilage
Human costal cartilage was extracted with tris buffer (0.1 fhol/1, pH 7.5), containing 0.5 mol/1 KC1, 10 mmol/1 benzamidine hydrochloride, 5 mmol/1 EDTA, l mmol/1 iodoacetate and 0.1 mmol/l phenylmethanesulphonyl fluoride for 20 h at 4 °C. After centrifugatiön at 5000g for 15 min the extract was treated with hyaluronate-4-glycanohydrolase (33 kU/1; 4 h; 37 °C) and dialysed exhaustively against 0.1 mol/1 tris buffer, 0.1 mol/1 NaCl (pH 8.5). After centrifugation of the solution (50000g; 30 min; 4 °C) Xylosyltransferase was enriched by ion exchange chromatography on Q-sepharose Fast Flow. Xylosyltransferase-containing fractions were concentrated by ultrafiltration (Amicon, -1 ) and stored at -70 °C.
Patients and reference group
We investigated 131 synovial fluids and 79 sera from patients with inflammatory and non-inflammatory joint diseases: rheumatoid arthritis (n = 24; 18 females and 6 males, age: 32-78 years, mean: 57.2 years); osteoarthrosis (n = 32; 20 females and 12 males, age: 47-83 years, mean: 61.8 years); ankylosing spondylitis (n = 10); Reiter's syndrome (n = 4); septic arthritis (n = 6); arthritis urica (monosodium urate crystals detected in synovia cell pellet) (n = 30; l female and 29 males, age: 30-80 years, mean: 52.3 years); calcium pyrophosphate deposition disease (pseudogout) (n = 18; 7 females and 11 males, age: 29-85 years, mean: 61.1 years); psoriatic arthritis (n = 7). In 79 cases synovial fluid and serum were taken simultaneously from the same patients.
The diagnosis of rheumatoid arthritis was based on the criteria of the American Rheumatism Association. The patients suffering from ankylosing spondylitis met the New York and Rome criteria. Microorganisms were shown to be present in all synovial fluids of patients with septic arthritis. Xylosyltransferase activities were also determined in sera of randömly selected blood donors (reference group) (n = 20; 6 females and 14 males, age: 19-53 years, mean: 33.4 years).
Preparation of Substrates
Preparation of core protein from bovine nasal septum cartilage
Chondrpitin sulphate proteoglycan was extracted from bovine nasal septum cartilage with 4 mol/1 guanidine hydrochloride and purified by density gradient centrifugation under dissociative conditions in 4 mol/1 guanidine hydrochloride and caesium chloride (initial density 1.5 kg/l) üsing the method of Sajdera & Hascall (8) . After digestion with testicular hyaluronate-4 i -glycanohydrolase (9), the freeze-dried chondroitin sulphate proteoglycan preparation, which must be completely ffee from water, was deglycosylated either with 70% hydrogen fluoride in pyridine (10, 11) or with trifluoromethane sulphonic acid (12) . The resuitirig core protein preparations were investigated for serine content by amino acid anälysis.
Preparation of silkfor assay
Silk from Bombyx mori (l g) was dissolved in 10 ml of 600 g/l lithium thiocyanate (13, 14) with stirring and gentle heating. After dilution with deionized water to about 80 ml, the solution was filtered, dialysed for 48 h against deionized water until free of thiocyanale, and equilibrated with tris buffer (0.1 mol/1, pH 7.0). Subsequently, the volume was adjusted to 100 ml and 0.5 ml fractions of the silk solution were stored at -70 °C.
Assay of Xylosyltransferase activity
Xylosyltransferase activity was assayed by a procedure which has been described previously (15, 16) ]xylose (specific activity: 9.88 TBq/mol = 267 nCi/nmol) and 0.5 μιηοΐ of KF in tris buffer (0.1 mol/1, pH 7.0). After incubation of the reaction mixture for 45 min at 37 °C, the reaction was terminated by adding 10 μΐ of EDTA (0.125 mol/1) and cooling the mixture in an ice-bath. Control incubation mixtures without exogenous acceptor (specimen blank) were kept at 0 °C for 45 min. In order to separate non-incorporated UDP-xylose from xylosylated silk, each reaction mixture was applied to Schleicher & Sch ll No. 2043 b mgl paper over an area of approximately 2cm 2 for descending paper chromatography. Nonbound UDP-xylose was eluted with ethanol/ammonium acetate (l mol/1, pH 5.5; 7 + 3 by vol.) for 48 h. After drying, 9 cm 2 pieces were transferred to a scintillation vial. Subsequently, l ml of water and 10 ml of scintillation fluid were added and the radioactivity was measured using a liquid scintillation counter (LKB Rack Beta II, Bromma, Sweden).
In comparative studies the following acceptor proteins were also used: core protein from HFrdegraded and trifluoromethane sulphonic acid-degraded proteoglycan of bovine nasal septum cartilage, and the synthetic peptides Leu-Pro-Ser-Gly and Pro-Ser-Gly. All experiments were carried out in the presence of an excess of the Substrates (13.8^-23-fold K m ) in order to reach F max . The results were expressed s enzyme activity (xylose, nmol · min" 1 · l" 1 ) or acceptor activity (xylose, nmol · min" 1 · mmol~l serine).
In diagnostic studies the detefmination of Xylosyltransferase activity in synovial fluids and ser f patients with chronic joint diseases and the reference gr p was carried out only with silk s Substrate.
Radioactivity of acceptor-bound [
i4 C]xylose and the specific aetivity of UDP-/>-i 14 C]xylQse were used to calculate Xylosyltransferase activity (Bq χ 5.574 = mu ).
Evaluation of imprecision, detection limit, and working r nge pf the Xylosyltransferase assay
The imprecision of the Xylosyltransferase determination was investigated with synovial fluids at 3 different activity levels (2.71, 4.89, and 6.85 m /1). Within-run imprecision was qbtained by analysis of 8 replicate samples of each pool. Betweenday imprecision was calculated from the results obtained from the same synovial fluid pools, which were stored in small aliquots at -70 °C, on 6 different days spread over a 4-week period.
For the investigation of the detection limit of the assay, synovial fluid was heated for 30 min at 56 °C, in order to completely abolish the enzyme activity. Thereafter the Xylosyltransferase l| J· Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 8 activity was assayed in 10 parallel trials and the detection limit (mean vaiue H-3 SD) was calculated from the intra-assay Variation.
To investigate the linearity of the assay, serial dilutions from a tissue extract of human costal cartilage with high Xylosyltransferase activity (70.3 mU/1) were examined. Each solution was analysed in duplicate.
In order to evaluate the recovery of Xylosyltransferase activity, inactivated aliquots (56 °C; 30 min) of inflammatory and noninflammatory synovial fluids were spiked each with 2 different Xylosyltransferase activities from human costal cartilage (1.1 and 10.9 mU/1) and the recovery rates were expressed s percent of the added activities.
Effect of agents on Xylosyltransferase activity
Fibrinogen
The effect of human fibrinogen on Xylosyltransferase activity was investigated in synovial fluid, serum and tissue extract from human costal cartilage, supplemented with· bovine serum albumin (l 8 g/l).
Fibrinogen concentrations between 0 and 21.5 g/l in the incubation mixture were used. Xylosyltransferase activity was also determined in fibrinogen-containing plasmas and corresponding fibrinogen-depleted sera of blood donors (n = 20).
Chondroitin sulphate peptidoglycans and heparin
Tissue extracts of human costal cartilage were incubated with chondroitin sulphate peptidoglycans of different degree of sulphation (SO|~, 0.31-0.96 mol/mol disaccharide) and with a persulphated peptidoglycosaminoglycan (SO|~, 4 mol/mol disaccharide) in a concentration r nge between 0 and 1000 μιηοΐ/ΐ galactosamine per assay.
The effect of heparin on Xylosyltransferase activity was examined in a concentration r nge of 0 to 566 USP units per ml of incubation mixture, also using serum of blood donors.
Native elastasefrom granulocytes
A tissue extract of human costal cartilage was incubated with deflned quantities of human granulocyte elastase (1.86, 18.6, and 186 mg/1) during 140 min. After an incubation time of 0, 45 and 140 min, aliquots were taken and immediately mixed with the elastase inhibitor phenylmethanesulphonyl fluoride to reach a final concentration of 0.1 mmol/1. The complete abolition of elastase activity in the aliquots was checked by a method described previously (17) . Xylosyltransferase activity was measured by the method described above.
Xylosyltransferase activity in cells of the synovial System
Xylosyltransferase activities were investigated in human hip articular cartilage, cultured synovial fibroblasts, pellet of synovia cells from synovial fluids with different degree of inflammation, and in blood granulocytes.
The hip articular cartilage derived from morphologically unchanged biopsy material and was homogenized before extraction. Synovial cells were taken from tissue pieces of the kneejoint capsule obtained during meniscectomy and maintained in monolayer cultures. The synovial cell pellet was obtained after centrifugation (750 g, 5 min) of fresh synovial fluids. Granulocytes were isolated from the buffy coat of centrifuged stored blood by density gradient centrifugation in the presencc of ficolL Lysis of the differcnl cells in tris buffer (0.1 mol/1, pH 7.4) was achieved by repeated deep-freezing and thawing and subsequent trcatment by ultrasound. After centrifugation (10 000 g; 30 min) Xylosyltransferase activities were measured in the supernates.
Other methods
Elastase in complex with a r proteinase inhibitor was determined by an enzyme immunoassay described previously (18) .
Determination of protein content was done by the method of Lowry (19) , using bovine serum albumin äs Standard.
Quantitation of serine residues of the different acceptors was carried out with a Biotronik LC 6000 E amino acid analyser after hydrolysis in 6 mol/1 HC1 at 110°C for 24h. Galäctos-amine was detennined by the same method after hydrolysis of the sample with 3 mol/1 HC1.
Estimation of the cell count in the native synovial fluids was performed with a Neubauer haemocytometer. In synovial fluids with high cell counts predilution with 9 g/l NaCl was necessary. Synovial ceils were differentiated after centrifugation of the native synovial fluids for 15 min at 1000# and staining of the cell pellet on a slide, according to the method of Pappenheim (20) . In order to facilitate the spreading of the cells, the viscous cell pellet was depolymerized by short-term preincubation with 5 (16 units)'<)f hyaluronate-4-glycanohydrolase. The granulocyte number was calculated from its percentage of differential synovia cell count in the total cell count measured.
Statistical analysis
The linear regression function was evaluated according to the method ofPearson. The Spearman rank correlation coefflcients were calculated to prove significant correlations between Xylosyltransferase activities in synovial fluids and sera of patients with different chronic joint diseases. Differences in mean values were examined by the Kruskal-Wallis H-test and the Wilcoxon signed ranks test (21); P values < 0.02 were considered äs significant.
Results
Precision, accuracy, working ränge, and detection limit of the Xylosyltransferase assay
The intra-assay coefficients of varation, calculated from measurements of samples with high (mean value = 6.85 mU/1), intermediate (mean value = 4.89 mU/1, and low (mean value = 2.71 mU/1) Xylosyltransferase activities, were 7.5%, 8.2% and 9.5%, respectively. Using aliquots of these samples for evaluation of the inter-assay imprecision, coefficients of Variation of 10.2%, 11.1%, and 11.8% were found.
Data on accuracy are not available, since Standard reference material is not established yet. Nevertheless, synovial fluids of patients with inflammatory and non-inflammatory joint diseases, mixed with tissue extracts of human costal cartilage gave recovery rates close to 100% (ränge 97.9-103.6%). The detection limit of Xylosyltransferase activity was found to be 0.15 mU/1. The working ränge of the assay is between 0.5 and 40 mU/1 ( fig. 1) . Thus, it was not necessary The enzyme activity was determined in dilutions of a xylosyltransferase-enriched tissue extract of human costal cartilage.
to predilute samples of synovial fluid and serum, since all Xylosyltransferase activities determined in these body fluids were within the working ränge.
Xylosyltransferase activities in synovial fluid and serum remained unehanged for at least l week at 4 °C, and at -70 °C for longer than 6 months. The enzyme loses about 10 -20% activity in l week when kept at room temperature.
Studies with different Substrates
Silk has been shown to bfe the Substrate with the highest incorporation rate in the Xylosyltransferase assay, compared with bovine HF-and CFsSOaHdegraded proteoglycans, and the synthetic peptides Leu-Pro-Ser-Gly and Pro-Ser-Gly (tab. 1). No significant incorporation of [ 14 C]xylose was observed when the peptides were used. While the K m values of silk and HF-degraded proteoglycan (core protein I in tab. 1) are in the same ränge, the corresponding enzyme and acceptor activities showed clear differences. The enzyme activity (incorporation of xylose, nmol · min" 1 -l"" 1 ) of Xylosyltransferase in the presence of silk was 3.7 and 1.8 times higher than that in the presence of the HF-and CF 3 SO3H-degraded proteoglycans, respectively. The acceptor activity of silk (incorporation of xylose, nmol · min" 1 · mnjpl" 1 serine) exceeds that of HF-degraded proteoglycans by a factor 2.
No influence of an endogerious acceptor was observed in any case, since the incubation withoüt exô genous acceptor did not result in a significant incorporation of [ Xylosyltransferase activity in human cells
Examination of defined cells of the synovial System demonstrates the presence of Xylosyltransferase activities predominantly in articular cartilage chondrocytes (41 -196 μΤ-J/g wet weight). A minor enzyme activity (< 8 μΙΙ/10 6 cells) was also detectable in cultured synovial fibroblasts, which are able to synthesize small amounts of chondroitin sulphate (< 10% of the total glycosaminoglycans). Xylosyltransferase activity was found neither in the total synovia cell pellet from inflammatory joint effusions nor in granulocytes.
Effect of fibrinogen on Xylosyltransferase activity
When we detennined Xylosyltransferase activities in sera and plasmas of blood donors (n = 20), significantly lower enzyme activities were found in all fibrinogen-containing plasma samples. The mean value in plasma was diminished to 46.3% (SD = 2.8%) of that in serum. Moreover, the addition of human fibrinogen to serum caused a marked Inhibition of Xylosyltransferase activity ( fig. 2) . At physiological concentfations the degree of Inhibition was about 50%. In synovial fluids and tissue extracts of human costal cartilage, however, the fibrinogen-induced Inhibition was less pronounced (22% and 12% f Inhibition in the presence of physiological copicentrations of fibrinogen, respectively) ( fig. 2 ).
Inhibition studies with chondroitin sulphate peptidoglycans and heparin
Chondroitin sulphate peptidoglycans and glycosaminoglycan polysulphates show dose-dependent Inhibition of Xylosyltransferase activities (fig. 3) 
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Chondroitin sulphate [galactosamine, μ,ηηοΐ/ΐ] fig. 4) . Heparin added to the assay mixtüre at concentrations usually found in plasma during therapy (0.2 -1 USP units/ml), caused only a slight Inhibition (2-5%) of serum Xylosyltransferase activity. However, in the presence of heparin concentrations, which are used in blood sampling to prevent clotting (10 -15 USP units/ml plasma), the serum Xylosyltransferase activity was inhibited by about 40%. The inhibitory effect of heparin is more pronounced on Xylosyltransferase activities from tissue extracts of human costal cartilage ( fig. 4 ). Effect of native granulocyte elastase on Xylosyltransferase activity
Xylosyltransferase activity was almost completely inhibited after incubation of tissue extracts of human costal cartilage with granulocyte elastase (186 mg/1). At a lower elastase concentratipii of 18.6 mg/1 the Xylosyltransferase activity was diminished to 61.4% and 9.4% of the initial activity after incubation föf 45 and 140 min, respectively ( fig. 5 ).
Xylosyltransferase activities in synovial fluids and sera of patients with chronic joint diseases In synovial fluids and sera of patients with chronic joint diseases Xylosyltransferase activities ranged from 0.5 to 22.0 rnU/1 and from 0.8 to 5.6 mU/1, respectively ( fig. 6 ). The parallel determination of Xylosyltransferase activity in synovial fluid and serum of the säme patients showed that in more than 80% of the synovial fluids enzyme activities were higher than those of the corresponding sera ( fig. 7) . How* ever, no significant correlation between Xylosyltransferase activity in synovial fluids and that in sera was observed. The serum Xylosyltransferase activities of patients with chronic joint diseases were not significaiitly dif- ferent ( fig. 6 ) and were similar to those of the reference group (median value: 1.42 mU/l, 90%-range:
The highest enzyme activities were found in synovial fluids of patients suffering from rheumatoid arthritis (median value: 5.56 mU/l, 90%-range: 3-2-22.0 mU/l). Xylosyltransferase activities determined in synovial fluids of patients with osteoarthrosis (median value: 2.50 inU/1, 90%-range: 0.8-4.8 mU/l), and calcium pyrophosphate deposition disease (med ian value: 1.78 mU/l, 90%-range: 0.6-3.2 inU/1) were significantly lower (P < 0.0001). That was also true for enzyme activities in synovial fluids of patients with arthritis urica (median value: 2.38 mU/l, 90%-range: 0.7-5.2 mU/l, P < 0.0001), although granulocyte counts and elastase concentrations in synovial fluids of patients with rheumatoid arthritis and arthritis urica were in the same ränge, showing a high degree of inflämmation, The median value and 90%-range (in parenthesis) of granulocyte nutnbers in synovial fluids of patients with rheumatoid arthritis and arthritis urica were 3.25 (0.96-11.0) and 7.76 (2.24-26.9) l O 9 /!, respectively. The corresponding values of granulocyte elastase were 7.65 (2.52-23.2) and 6.89 (1.56-30.2) ^/1, respectively. In synovial fluids of patients with arthritis urica, th § measured Xylosyltransferase activities were similar to those in osteoarthrosis (P = 0.741). Statistical analysis revealed no significant correlation between synovial fluid activity of Xylosyltransferase and corresponding granulocyte count or elastase concentration, respectively.
Discussion
Xylosyltransferase activity is present in the rough endoplasmic reticulum of chondrocytes of various species (6) . The present Information about the involvernent of the Xylosyltransferase in the biosynthesis of carbohydräte side chains of proteoglycans is mainly based on the investigations of Schwartz & Dorfman (22) , which suggest that the Xylosyltransferase molecule is provided with binding sites to UDP-xylose, the core protein and galactosyltransferase I. After xylosylation of serine residues in the core protein, the transfer of galactose from UDP-galactose to the xylose residue occurs. However, the course of the proteoglycan synthesis between formation of core protein and addition of carbohydräte side chains has not been elucidated in detail so far (23) . In analogy to glycoprotein synthesis (24) it is suggested that the initiation of chondroitin sulphate chains already occurs while the protein core is still nascent (5, 25) .
Only a little Information about the specificity of Xylosyltransferase is available. It is not known whether there is a specific Xylosyltransferase for each type of proteoglycan. According to previous findings, the in vivo Substrate for Xylosyltransferase is not a single, well-defined compound but rather a spectrum of molecules, ranging from the shortest possible nascent peptide capable of serving äs an acceptor in the first xylosyl transfer reaction to larger peptides species in which almost all of the reactive serine residues have been glycosylated. The only constant feature of the Substrate structure discovered so far is the presence of a glycine residue at the C-terminal side of the xylose-accepting serine residue (26) . Thus, the search for appropriate Substrates of the Xylosyltransferase was focused on proteins containing the Ser-Gly pair and it led to silk from Bombyx mori, which contains a large number of Ser-Gly sequences in the repeating hexapeptide Ser-Gly-Ala-Gly-Ala-Gly (13) . It should be emphasized that the presence of a Ser-Gly pair is not in itself sufficient to convey acceptor activity to a protein, since Collagen which contains several such groups is not an acceptor (27) . The K m values which have been reported for silk (182 mg/1) (13) and protein core of Sw/YA-degraded proteoglycan (143-240 mg/1) (13, 15) are similar, when expressed on a weight basis. Since precise Information regarding the relative proportions of reactive and unreactive serine residues is not available for either Substrate, the more appropriate comparison based on the molar concentrations of reactive serine residues cannot be made at the present time.
However, our study shows that the acceptor activity, i. e. the incorporation rates of [
C]xylose in our test
System, is about two to three times higher than that of the proteoglycan derivatives. Compared with core protein acceptors, which often show the disadvantage of considerably varying acceptor activities between different preparations, silk is more invariably available. Since the practical and economic advantages of using silk äs Substrate are evident, in our study this acceptor was employed to measure xylosyltransferase activities in synovial fluids and sera of patients with chronic joint diseases.
The xylosyltransferase activities which we have found in the synovial fluid of patients with chronic-inflammatory and degenerative joint diseases ranged between 0.5 and 22.0 mU/1. In the synovial System the articular cartilage represents the main source of these enzyme activities. Our study shows that low xylosyltransferase activity is also detectable in cultured synovial flbroblasts, which synthesize chondroitin sulphate (about 10% of total glycosaminoglycan production) in a^dition to hyaluronate, which is the main glycosaminoglycan. No xylosyltransferase activity was found in extracts of granulocytes and in synovia cell pellets, not even in highly inflammatory processes. It is generally accepted that tissue destruction in inflammatory joint diseases is caused by proteinases, which are released from granulocytes (28 -31) or other sources, like macrophages, synovial fibroblasts, and chondrocytes (32 -34) . Particularly elastase, which is secreted in large amounts from granulocytes, plays a crucial role in the destruction of articular cartilage in chronic inflammatory joint diseases, due to its ability to cleave the protein core and the hyaluronate binding region of proteoglycans (35 -37) .
Since proteoglycan fragments, which may serve äs a Substrate for xylosyltransferase, are released into the synovial fluid during inflammatory joint processes, we studied the influence of chondroitin sulphate peptidoglycosaminoglycans on the xylosyltransferase activity in vitro. Our studies have shown that the xylosyltransferase activity is inhibited by.chondroitin sulphate peptidoglycosaminoglycans äs a function of concentration and degree of sulphation, and furthermore that granulocytic elastase degrades xylosyltransferase activity. However, an effect of these factors on the enzyme activities measured in synovial fluids from patients with chronic joint diseases seems to be unlikely, since xylosyltransferase activities, added to synovial fluid in defined quantities, showed a high recovery.
When we determined xylosyltransferase activities in synovial fluid and serum of the same patient, no, significant correlation between serum activity and enzyme activity in the synovial fluid was found. While many of the synovial fluidsrexbititJhiigh enzyme activity, no parallel increase was oB'served in the corresponding sera. This mäy be due to the high dilutioii of the enzyme, which is released from the joint cavity into the blood. 'Data on the half life of the enzyme in blood are not yet available. Üloreover, the organ specificity of this parameter in serum is limited, since different tissues, e. g. liver. (38) and skin, niust be taken into account äs sources of xylosyltransferase activity. Our .study -rather suggests that the xylosyltransferase activity derived from articular cartilage can be specifically determined in blood only by an immunological method (radioimmunoassay, enzyme immunoassay).
The Inhibition studies with fibrinogen also suggest that various xylosyltransferase isoenzymes are present in blood. Addition of human fibrinogen to serum in physiological concentrations caused a marked Inhibition (about 50%) of xylosyltransferase activity. A similar degree of Inhibition was obseryed when we compared plasma enzyme activities with tfaose in the corresponding sera. The mechanism of the inhibitory effect of fibrinogen is still unclear. However, the degree of Inhibition seems to depend on the origin of the xylosyltransferase isoenzyme, since the blood xylosyltransferase is inhibited more than that derived from human costal cartilage (about 12% of Inhibition at physiological concentrations of fibrinogen). The intermediate degree of Inhibition of xylosyltransferase activity (about 22%) in synovial fluids from patients with chronic joint. diseases may be due to the presence of xylosyltransferase isoenzymes from sources outside the joint, resultiiig from an enhanced permeability of the blood-synovia-barrier in inflammatory joint processes.
The xylosyltransferase activities in synovial fluids showed considerable differences between clinically defined joint diseases. The highest enzyme activities were found in the synovial fluids of patients with rheumatoid arthritis. It is an interesting finding that the xylosyltransferase activities in synovial fluids of patients with arthritis urica were müch lower and in the same ränge äs those in osteoarthrosis, although the granulocyte count and elastase concentration, reflecting the degree of inflammation, corresponded with those in synovial fluids of patients with •rheumatoid arthritis. Thus, it is obvious that the xylosyltransferase activity represents no parameter of inflammation in the precise sense, altfeough in inflammatory processes the increased destruction of chondrocytes may lead to an enhanced release of xylosyltransferase.
There was no correlation between Xylosyltransferase activity in the synovial fluid and granulocyte number or elastase concentration. The higher Xylosyltransferase activities in synovial fluids of patients with rheumatoid arthritis, compared with those of patients with arthritis urica and osteoarthrosis, is probably attributed to an increased cartilage destruction during the course of this disease.
Our results demonstrate that Xylosyltransferase activity in the synovial fluid represents an appropriate clinical chemical parameter, indicating the degree of cartilage destruction in chronic joint diseases. In serum, however, various Xylosyltransferase isoenzymes from different tissue sources may be present. The employment of an immunoassay, which is now under development by our group, seems to be an essential requirement for the determination of cartilage-specific Xylosyltransferase in serum.
